Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Small Molecules
Filter     Order     Display # 
Date Item Title
22 May 2008 Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
22 May 2008 ARIAD Initiates Phase 1 Clinical Trial of its Investigational Oral Multi-Targeted Kinase Inhibitor, AP24534, in Patients with Hematological Cancers
22 May 2008 Lundbeck acquires European commercialization rights for Flurizan(R) from Myriad, USA - a new drug in final phase III development for the treatment of Alzheimer's disease
22 May 2008 DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
22 May 2008 Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
22 May 2008 QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy
21 May 2008 Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
21 May 2008 Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
21 May 2008 Adolor and GlaxoSmithKline Announce FDA Approval of Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)
21 May 2008 Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
21 May 2008 NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid Cancer
21 May 2008 Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
21 May 2008 FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
21 May 2008 Data from Phase IIb trial of Elocalcitol in BPH presented at the annual meeting of the American Urological Association (AUA)
21 May 2008 Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
21 May 2008 Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
21 May 2008 Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
21 May 2008 Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
21 May 2008 Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week
21 May 2008 QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
21 May 2008 Tioga Pharmaceuticals’ Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
20 May 2008 Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
20 May 2008 Dynogen presents results of its positive phase 2a IBS-c study with DPP733
20 May 2008 Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms
20 May 2008 Ceragenix Announces Results of a Comparison Study of the Safety and Efficacy of EpiCeram(R) Cream for the Treatment of Mild to Moderate Pediatric Atopic Dermatitis
20 May 2008 Commencement of Phase II study for Colal-Pred(R) in the US
20 May 2008 Ceftobiprole shows high cure rates in patients hospitalized with community-acquired pneumonia
20 May 2008 KAI Pharmaceuticals Advances Third Product Candidate into Clinical Studies
20 May 2008 Balsalazide 3.3 Grams Twice-Daily Shows Significant Improvement in Bowel Function and Some Quality of Life Measures as Early as Week Two
19 May 2008 RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer
19 May 2008 Amikacin Inhale shows promising results in Phase II Study
19 May 2008 Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
19 May 2008 Positive Clinical Data with Santarus' ZEGERID Capsules in Controlling 24-Hour Gastric Acidity Presented in DDW Abstract
19 May 2008 Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
19 May 2008 New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
19 May 2008 ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
19 May 2008 Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet
19 May 2008 TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
19 May 2008 Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
16 May 2008 Pharmacopeia's First-In-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
16 May 2008 Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
16 May 2008 Landmark ATHENA Study Findings With Multaq(R) (Dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
16 May 2008 ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
16 May 2008 GSK announces results of first Phase III trial evaluating Tykerb(R)/Tyverb(R) (lapatinib) plus Herceptin(R) (trastuzumab)
16 May 2008 Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886)
16 May 2008 E7389 Demonstrated Anti-tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
16 May 2008 ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
16 May 2008 Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
16 May 2008 Inspire Receives Milestone Payment for Completion of Phase 3 Testing in Japan for Dry Eye Program
16 May 2008 Arpida announces FDA acceptance of the Iclaprim new drug application
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 451 - 500 of 5215

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics